156 related articles for article (PubMed ID: 19917747)
1. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
Reuman EC; Bachmann MH; Varghese V; Fessel WJ; Shafer RW
Antimicrob Agents Chemother; 2010 Feb; 54(2):934-6. PubMed ID: 19917747
[TBL] [Abstract][Full Text] [Related]
2. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
[TBL] [Abstract][Full Text] [Related]
3. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
4. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
6. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
[TBL] [Abstract][Full Text] [Related]
7. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
8. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
[TBL] [Abstract][Full Text] [Related]
9. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
[TBL] [Abstract][Full Text] [Related]
10. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
[TBL] [Abstract][Full Text] [Related]
11. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
13. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
14. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
[TBL] [Abstract][Full Text] [Related]
15. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
[TBL] [Abstract][Full Text] [Related]
16. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
Huang W; Frantzell A; Fransen S; Petropoulos CJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
[TBL] [Abstract][Full Text] [Related]
19. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
[TBL] [Abstract][Full Text] [Related]
20. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
